We report here the case of a child with a known muscular abnormality and susceptibility to malignant hyperthermia who abruptly died after receiving a therapeutic dose of ondansetron. Also, we discuss the pharmacodynamic relationship of ondansetron to malignant hyperthermia in a susceptible host.
Subjects:
For Your Benefit
Copyright © 2010 by the American Academy of Pediatrics
2010
You do not currently have access to this content.
